Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2010 Dec;6(4):105-114.
doi: 10.1007/s12014-010-9053-0. Epub 2010 Sep 10.

Quantitative iTRAQ-Based Proteomic Identification of Candidate Biomarkers for Diabetic Nephropathy in Plasma of Type 1 Diabetic Patients

Quantitative iTRAQ-Based Proteomic Identification of Candidate Biomarkers for Diabetic Nephropathy in Plasma of Type 1 Diabetic Patients

Anne Julie Overgaard et al. Clin Proteomics. 2010 Dec.

Abstract

INTRODUCTION: As part of a clinical proteomics programme focused on diabetes and its complications, it was our goal to investigate the proteome of plasma in order to find improved candidate biomarkers to predict diabetic nephropathy. METHODS: Proteins derived from plasma from a cross-sectional cohort of 123 type 1 diabetic patients previously diagnosed as normoalbuminuric, microalbuminuric or macroalbuminuric were enriched with hexapeptide library beads and subsequently pooled within three groups. Proteins from the three groups were compared by online liquid chromatography and tandem mass spectrometry in three identical repetitions using isobaric mass tags (iTRAQ). The results were further analysed with ingenuity pathway analysis. Levels of apolipoprotein A1, A2, B, C3, E and J were analysed and validated by a multiplex immunoassay in 20 type 1 diabetic patients with macroalbuminuria and 10 with normoalbuminuria. RESULTS: A total of 112 proteins were identified in at least two out of three replicates. The global protein ratios were further evaluated by ingenuity pathway analysis, resulting in the recognition of apolipoprotein A2, B, C3, D and E as key nodes in the top-rated network. The multiplex immunoassay confirmed the overall protein expression patterns observed by the iTRAQ analysis. CONCLUSION: The candidate biomarkers discovered in this cross-sectional cohort may turn out to be progression biomarkers and might have several clinical applications in the treatment and monitoring of diabetic nephropathy; however, they need to be confirmed in a longitudinal cohort. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1007/s12014-010-9053-0) contains supplementary material, which is available to authorized users.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
a MS/MS spectrum of the C-terminal peptide from apolipoprotein E (sequence QAAVGTSAAPVPSDNH). The assignment of the peptide is illustrated by the y- and b-ions in the spectrum. b MS/MS spectrum of the peptide with the sequence LLDNWDSVTSTFSK from apolipoprotein A1
Fig. 2
Fig. 2
Top-rated network generated by ingenuity pathway analysis on the N/DMN ratio. Red nodes indicate that the protein is upregulated in the DMN group compared to the N group. Stronger red colours indicate higher regulation of the complex
Fig. 3
Fig. 3
a Network shapes. Figure legend for the IPA network. https://analysis.ingenuity.com/pa/info/help/help.htm#legend.htm. b Relationships. Figure legend for the molecular relationships in the IPA network. https://analysis.ingenuity.com/pa/info/help/help.htm#legend.htm
Fig. 4
Fig. 4
Ratios of the lipoproteins identified by iTRAQ- and Luminex-based assays. The iTRAQ ratio is between the N/DMN and the Luminex ratio is the N/SlD, N/RD and N/SlD + RD ratios

Similar articles

Cited by

References

    1. Finne P, Reunanen A, Stenman S, Groop P-H, Gronhagen-Riska C. Incidence of end-stage renal disease in patients with type 1 diabetes. JAMA. 2005;294:1782–87. - PubMed
    1. Daneman D. Type 1 diabetes. Lancet. 2006;367:847–58. - PubMed
    1. Cameron JS. The discovery of diabetic nephropathy: from small print to centre stage. J Nephrol. 2006;19:75–87. - PubMed
    1. Kilpatrick ES, Rigby AS, Atkin SL. HbA1c variability and the risk of microvascular complications in type 1 diabetes: data from the DCCT. Diabetes Care. 2008;31:2198–202. - PMC - PubMed
    1. Mogensen CE. Long-term antihypertensive treatment inhibiting progression of diabetic nephropathy. Brit Med J. 1982;285:685–88. - PMC - PubMed